The topic of licensing came up recently, as in does CYDY license LL by indication, or perhaps geography, or does the company sign on with one BP exclusively? Thoughts or opinions? I don't recall the company giving us any indication as to how they might proceed in partnership.

Google's response to my initial query on the general topic:

Quote:

---

Yes, a drug company can license the rights for a drug to multiple pharmaceutical companies for different indications, though it depends on the licensing agreement's terms, which can be either exclusive or non-exclusive. A licensor can also restrict the licensing to specific geographic territories or types of use. The choice between these licensing structures influences the market penetration and strategic implications of the deal.

Licensing Structures

Exclusive License:
The licensee has the sole right to use the drug for a specific indication or territory, preventing both the licensor and any other company from exploiting it.

Non-Exclusive License:
The licensor can grant rights to multiple companies, allowing for broader market penetration of the drug for different indications.

Sole/Co-Exclusive License:
The licensor cannot license the drug to other companies but can still use or sell it themselves.
...

Example of Multi-Indication Strategy
A drug might be licensed to one company for a common condition like cancer, and to a different company for an unrelated condition, such as a specific autoimmune disease. This strategy allows the drug innovator to broaden access and market presence without having to manage multiple product lines itself...

---